Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences By Investing.com
Update: 2025-10-30
Description
Viking Therapeutics' stock surged as they announced their VK2735 obesity program will be featured at major medical conferences. The company plans to share data from their Phase Two clinical trial, VENTURE, and present the design for their VANQUISH-2 study at ObesityWeek and the American Heart Association meetings. VK2735, a dual agonist targeting GLP-1 and GIP receptors, aims to address obesity and metabolic disorders. The upcoming conferences will provide insights into the drug's potential for treating common health issues.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
